Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Aug 30, 2021 9:46pm
263 Views
Post# 33786208

RE:RE:RE:converting data

RE:RE:RE:converting dataYes. Blunder on the 15 when the math only works as 12.

I was just going to write about the optimized study chart. I actually think that that only makes sense as a continuation of the new way of separating out optimized therapy patients.

12 would make sense
- 3 reported last newsletter (2 CR and 1 NR but note that the 1 NR is sometimes label partial R)
- 3 pending last newsletter (4 in the SEDAR report)everyone has been talking about these 3 -4 as the next installment)
- 6 pending (sedar July documents went from 4 pending to 6 pending.

I suspect that they have decided to label the 1 NR as PR (likely the patient that passed away).

So using the format they used in the last newsetter

Assessment day 90
4 CR
2 PR
6 Pending
Total 12

I think the only way that the NR number on the full 27 can drop from 9 to 8 is if they re-allocate the NR patient to the PR category as had negative cytology before passing. How else can the 90 day total drop by one patient.

So in answer to what everyone was waiting.

I think the 4 patients that were pending on the July SEDAR documents have become
2 NR
1 PR
1 pending

and I think that the incorrectly labelled NR was relabelled PR

So stepping back, of the patients who hav ever recieved optimized therapy, there ar now 12 + 3 from phase 1b.

6 of those are pending.

9 are known
for the set of 9 the results at 90 days are
6 CR (66%)
2 PR (1 new and the correctly assigned passed away patient with neg cytology)
1 NR

6+2 = 8/9

So of all the patient to ever GET OPTIMIZED TREATMENT (excluding pending 6)
88.9% responded.

looking good. assuming the company can manage all their other issues.....
<< Previous
Bullboard Posts
Next >>